Devaki Shilpa Surasi, MD, CMQ
Department of Nuclear Medicine, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Diagnostic and Interventional Imaging, Division of Diagnostic Imaging, McGovern Medical School, Houston, TX
Associate Professor, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Diagnostic and Interventional Imaging, McGovern Medical School at UTHealth Houston, Houston, Texas
Associate Professor, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Patient Safety and Quality Officer, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Research Interests
test
Education & Training
Degree-Granting Education
| 2006 | Gandhi Medical College affiliated with NTR University of Health Sciences, Hyderabad, IN, MBBS in Medicine and Surgery |
Postgraduate Training
| 2015-2018 | Clinical Residency, Diagnostic Radiology, The University of Oklahoma Health Sciences, Oklahoma City, Oklahoma |
| 2012-2015 | Clinical Residency, Clinical Nuclear Medicine, University of Alabama at Birmingham, Birmingham, Alabama |
| 2011-2012 | Clinical Internship, Surgery, Morehouse School of Medicine/Grady Memorial Hospital, Atlanta, Georgia |
| 2009-2011 | Research Fellowship, Boston University Medical Center, Boston, Massachusetts |
| 2007-2008 | House Officer, Baalajee Hospital, Hyderabad |
| 2006-2007 | Clinical Internship, Gandhi Hospital, Secunderabad |
Licenses & Certifications
| 2019 | American Board of Radiology |
| 2018 | Certified in Clinical Densitometry by The International Society of Clinical Densitometry |
| 2018 | Texas Medical License |
| 2015 | American Board of Nuclear Medicine |
| 2015 | American Board of Medical Quality |
| 2007 | Medical Council of India |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, 2018 - 2023
Chief Resident, The University of Alabama at Birmingham, Birmingham, AL, 2014 - 2015
Administrative Appointments/Responsibilities
Primary Authorized User, Institutional Radioactive Materials License, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Faculty Lead, Clinical PET/MRI Pilot Program, Department of Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Other Professional Positions
Chair, ACR–ACNM–SNMMI–SPR Practice Parameter for the Performance of Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI), 2024 - Present
Co-Chair, ACR–ACNM–ARS–SNMMI Practice Parameter for Prostate-Specific Membrane Antigen (PSMA) Therapy, 2024 - Present
Chair, ACR–ACNM–SNMMI Practice Parameter for the Performance of Fluorine-18 Fluciclovine PET/CT for Recurrent Prostate Cancer, 2022 - 2023
Member of the Prostate Cancer Working Group, Society of Nuclear Medicine and Molecular Imaging (SNMMI), Reston, VA, 2022 - 2025
Member, American College of Radiology (ACR), Reston, VA, 2021 - Present
Member, Society of Abdominal Radiology (SAR), East Dundee, IL, 2020 - Present
Appropriateness Criteria - Nuclear Medicine Expert Representative, American College of Radiology (ACR), Reston, VA, 2019 - Present
Member Reference Committee III, American College of Radiology (ACR), Reston, VA, 2016
National Quality Scholarship & Mentorship Program Director, American College of Medical Quality (ACMQ), Bethesda, MD, 2015 - 2016
Quality Committee, Society of Nuclear Medicine and Molecular Imaging (SNMMI), Reston, VA, 2015 - 2018
Stephen Amis Fellow in Quality and Safety, American College of Radiology (ACR), Reston, VA, 2015 - 2016
Intramural Institutional Committee Activities
Member, Radiation Safety Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Cost of Care Committee: PET Optimization and ICU Imaging, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Nuclear Medicine Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Extramural Institutional Committee Activities
Member, PSMA-RADS Subcommittee of PI-RADS, American College of Radiology (ACR), 2025 - Present
Reviewer, Faculty Academic Career Development (FACD) Academy Applications - Cohort #4, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Chair, Nuclear Medicine Peer Review Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, PET/CT QA Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Space Recommendations and Timeline: Theranostics, The University of Texas MD Anderson Cancer Center, 2024 - Present
Mentor, LEADing Self Accelerate, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Department Representative, Mid-Career Faculty Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Dermatology Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Member, Hospital Medicine Chair Search Round Two Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2023
Member, Structured Reporting Template Governance Committee (SRTGC), The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Diagnostic Imaging Director of Wellness Selection Panel, The University of Texas MD Anderson Cancer Center, 2023 - 2023
Member, Infectious Diseases, Infection Control, and Employee Health Chair Search Round Two Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2023
Member, Employee Engagement Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Diagnostic Imaging - Patient Safety Quality Officer (DI-PSQO) Search Interview Panel, The University of Texas MD Anderson Cancer Center, 2022
Lead, Diagnostic Imaging - Department Mentoring, The University of Texas MD Anderson Cancer Center, 2022 - Present
Institutional Faculty Peer Messenger, Center for Professionalism Support and Success (CPSS), The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Diagnostic Imaging - Research Functional Committee (DI-RFC) Awards and Honors Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Faculty Appraisal Working Group, The University of Texas MD Anderson Cancer Center, 2022 - Present
Chair-Elect, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Inaugural Cohort Faculty Participant, Faculty Academic Career Development, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Member, Theranostics Technology & Capital Implementation Meeting, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Prostate Cancer Trial Priorities Meeting, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Nuclear Medicine Focus Group, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Theranostics Program Development & Operations Committee (PDOC), The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Diagnostic Imaging Safety, Quality, Value Functional Committee (DI-SQVFC), The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Research Functional Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Academic Policy Advisory Council, The University of Texas MD Anderson Cancer Center, 2021 - Present
Faculty Advisor, Research Infrastructure Project, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Theranostics Taskforce, The University of Texas MD Anderson Cancer Center, 2021 - 2021
Member, Cervical Cancer PET/MRI Review Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Tumor Measurement Initiative Structured Reporting and Innovation, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Prostate Cancer PET/MRI Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Nuc Med Physics Faculty Recruitment Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2021
Co-Chair, Grand Rounds Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2024
Member, Prostate Cancer Treatment Algorithm, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Academic Leadership Team, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Nuclear Medicine Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Radiation Oncology Strategic Initiative, Advanced Imaging Pillar, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2023
Member, Nuclear Medicine Advisory Committee for HALs, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Nuclear Medicine Peer Review Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Editorial Activities
Associate Editor, Radiology: Imaging Cancer Journal, 2022 - Present
Honors & Awards
| 2025 - Present | Faculty Excellence Award for Quality Improvement and Patient Safety, The University of Texas MD Anderson Cancer Center |
| 2024 - Present | Radiology Management Program, Association of University Radiologists |
| 2023 | Council of Early Career Investigators in Imaging, The Academy for Radiology & Biomedical Imaging Research |
| 2021 | 2021 Research Support from Blue Earth Diagnostics, $125,000 |
| 2020 | 2020 Radiation Oncology Cancer Imaging Program CCSG grant ($25,000) |
| 2020 | 2020 Radiation Oncology Strategic Initiative (ROSI) MDACC Seed Grant ($29,000), The University of Texas MD Anderson Cancer Center |
| 2019 - 2020 | RSNA/ASNR Comparative Effectiveness Research Training (CERT) Program, Chicago, RSNA |
| 2019 | AUR Academic Faculty Development Program, Association of University Radiologists |
| 2018 | ACR-AUR Research Scholar Program, ACR-AUR |
| 2017 | Trainee Stipend Award, ISMRM/SNMMI PET/MRI Workshop |
| 2017 - 2018 | 2018 Roentgen Resident/Fellow Research Award, RSNA R&E Foundation |
| 2017 | First Prize, Resident Poster, Oral Presentation, Oklahoma State Radiological Society Annual Meeting |
| 2017 | RSNA Student Travel Award, RSNA |
| 2016 | Radiology Leadership Institute Summit Scholarship (September 8-11, 2016), American College of Radiology (ACR) |
| 2015 - 2016 | Roentgen Resident/Fellow Research Award, RSNA R&E Foundation |
| 2015 - 2016 | Stephen Amis, Jr., MD Fellowship in Quality and Safety, American College of Radiology (ACR) |
| 2015 | Certified in Medical Quality, American Board of Medical Quality (ABMQ) |
| 2015 | National Quality Scholarship Award Program (March 26-28, 2015), American College of Medical Quality (ACMQ) |
| 2015 | SNMMI Future Leaders Academy Program (January 20-21, 2015), SNMMI Future Leaders Academy Program |
| 2014 - 2015 | "Eva Dubovsky" Molecular Imaging and Therapeutics Scholar Award for Academic Excellence, University of Alabama at Birmingham |
| 2014 - 2015 | UAB Chief Quality Resident Program |
| 2012 | Best Resident/Basic Scientist Trainee Paper, Second Prize |
| 2011 | Certificate of Merit, RSNA 2011 |
| 2010 | Certificate of Merit, ARRS 2010 |
| 2010 | Cum Laude Award, RSNA |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2026. Imaging and Therapy in Prostate Cancer. Invited. Texas Radiological Society 113th Annual Meeting. Houston, TX, US.
- 2023. PSMA PET Indications. Invited. PSMA PET Indications. Austin, TX, US.
- 2023. Prostate Cancer Imaging and Staging, including a Urologist's Perspective on PSMA Imaging. Invited. Prostate Cancer Imaging and Staging, including a Urologist's Perspective on PSMA Imaging. Sugar Land, TX, US.
National Presentations
- 2026. Phase 1B/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment-naïve patients with advanced clear cell RCC. Poster. 2026 ASCO Genitourinary Cancers Symposium. San Francisco, CA, US.
- 2026. Diagnostic performance of 18F-flotufolastat PET/CT compared with conventional imaging for detection of pelvic lymph node metastases in men with newly diagnosed prostate cancer: Descriptive post-hoc analysis from the phase 3 LIGHTHOUSE study. Poster. 2026 ASCO Genitourinary Cancers Symposium. San Francisco, CA, US.
- 2025. IAEA Session: Bridging medical imaging gaps across the world: Strategic Planning of Diagnostic and Interventional Radiology Services in Low- and Middle-Income Countries. Panelist. 2025 RSNA Annual Meeting. Chicago, IL, US.
- 2025. Medical Imaging at the Nexus of Global Health: An IAEA Perspective. Panelist. 2025 RSNA Annual Meeting. Chicago, IL, US.
- 2025. Imaging of High Risk and Advanced Prostate Cancer with Emphasis on MRI, PET/CT and PET/MRI. Invited. Society of Abdominal Radiology (SAR) Annual Meeting. Tucson, AZ, US.
- 2025. Understanding Radioligand Therapies for Advanced Prostate Cancer. Panelist. San Francisco, CA, US.
- 2025. PSMA-Based Therapy in Advanced Disease: Touching on Combination Sequencing. Invited. GU ASCO 2025 Annual Meeting. San Francisco, CA, US.
- 2024. Multimodal Imaging in Urogenital Cancers: Integrating PET, MRI, and CT. Invited. RSNA 2024 Annual Meeting. Chicago, IL, US.
- 2024. PET/MR vs. PET/CT Radiation Dose Comparison-Radiologist Perspective. Invited. RSNA 2024 Annual Meeting. Chicago, IL, US.
- 2024. Novel therapies including Alpha agents in Prostate Cancer. Invited. Interregional Training Course on Quality Management Audits in Nuclear Medicine Practices (QUANUM). Houston, TX, US.
- 2024. A Prospective Pilot Study Investigating 18F rhPSMA-7.3 PET/MRI to Detect Recurrent Disease and Guide Radiotherapy Planning in Patients with Biochemically Recurrent Prostate Cancer Post-Prostatectomy. Poster. American Society for Radiation Oncology (ASTRO) 66th Annual Meeting. Washington DC, US.
- 2024. Rapid Fire Case Review: PET Oncology, Radiology Review Track: Nuclear Medicine. Invited. American Roentgen Ray Society (ARRS) Annual Meeting. Boston, MA, US.
- 2024. Imaging of High Risk and Advanced Prostate Cancer with Emphasis on MRI, PET/CT and PET/MRI. Invited. Society of Abdominal Radiology (SAR) Annual Meeting. Hollywood, FL, US.
- 2024. PSMA theranostics. Invited. Academy Medical Imaging Technology Showcase. Washington, DC, US.
- 2023. Clinical Applications II - Session 9: Non-Oncology Applications. Panelist. Clinical Applications II - Session 9: Non-Oncology Applications. Los Angeles, CA, US.
- 2023. PSMA PET: Where are we at and where are we going?. Invited. PSMA PET: Where are we at and where are we going?, US.
- 2023. PSMA Ligand PET/CT Imaging in Prostate Cancer. Invited. International Atomic Energy Agency. Houston, TX, US.
- 2023. PSMA Targeted Radionuclide Therapy for Prostate Cancer. Invited. International Atomic Energy Agency. Houston, TX, US.
- 2023. Interactive Primer on Statistics: Study Design. Invited. Interactive Primer on Statistics: Study Design. Austin, TX, US.
- 2023. Rapid Fire Case Review: PET Oncology, Radiology Review Track: Nuclear Medicine. Invited. Rapid Fire Case Review: PET Oncology, Radiology Review Track: Nuclear Medicine. Honolulu, HI, US.
- 2023. Quality Indicators for Prostate Cancer Imaging Services. Invited. Quality Indicators for Prostate Cancer Imaging Services. Austin, TX, US.
- 2023. Imaging of High-Risk and Locally Advanced Prostate Cancer. Conference. Imaging of High-Risk and Locally Advanced Prostate Cancer. Austin, TX, US.
- 2022. SNMMI Symposium: The Role of PSMA Imaging and Therapy in Managing Prostate Cancer, PSMA therapy: Nuclear Medicine Perspective. Invited. SNMMI Symposium: The Role of PSMA Imaging and Therapy in Managing Prostate Cancer, PSMA therapy: Nuclear Medicine Perspective. Houston, TX, US.
- 2022. Nuclear Medicine. Invited. Nuclear Medicine, US.
- 2022. Role of Beta Emitters in the Management of Prostate Cancer. Invited. Role of Beta Emitters in the Management of Prostate Cancer. San Antonio, TX, US.
- 2022. Advances in Prostate Imaging with Emphasis on the Role of Molecular Imaging. Workshop. Invited. Advances in Prostate Imaging with Emphasis on the Role of Molecular Imaging. Workshop, US.
- 2022. Quality Indicators for Prostate Cancer Imaging Services. Workshop. Invited. Quality Indicators for Prostate Cancer Imaging Services. Workshop, US.
- 2021. PSMA Targeted Radionuclide Therapy of Prostate Cancer. Invited. PSMA Targeted Radionuclide Therapy of Prostate Cancer. Virtual.
- 2021. Imaging of High Risk and Very High Risk Prostate Cancer. Invited. Imaging of High Risk and Very High Risk Prostate Cancer, US.
- 2020. Imaging of High Risk and Very High Risk Prostate Cancer. Workshop. Invited. Imaging of High Risk and Very High Risk Prostate Cancer. Workshop, US.
- 2019. Imaging of High Risk Prostate Cancer: What the Urologist Wants to Know? Workshop. Invited. Imaging of High Risk Prostate Cancer: What the Urologist Wants to Know? Workshop, US.
- 2018. Evaluation of the Performance of PIRADv2 and Clinical Parameters (PSA, Prostate Volume, PSA Density) in Predicting Clinically Significant Disease on MRI Fusion Biopsy. Accepted for Oral Presentation at the ACR-AUR Research Scholar Program. Conference. Evaluation of the Performance of PIRADv2 and Clinical Parameters (PSA, Prostate Volume, PSA Density) in Predicting Clinically Significant Disease on MRI Fusion Biopsy. Accepted for Oral Presentation at the ACR-AUR Research Scholar Program, US.
- 2017. Utility of Longitudinal Measurement of the Liver on Ultrasound in Comparison to CT Liver Volume in Assessing Hepatomegaly. Accepted for Oral Presentation. Awarded Student Travel Award. Conference. Utility of Longitudinal Measurement of the Liver on Ultrasound in Comparison to CT Liver Volume in Assessing Hepatomegaly. Accepted for Oral Presentation. Awarded Student Travel Award, US.
- 2017. Approach to Heterotaxy: A Case Review. Poster and Oral Presentation. Awarded First Prize for Best Resident Poster. Conference. Approach to Heterotaxy: A Case Review. Poster and Oral Presentation. Awarded First Prize for Best Resident Poster, US.
- 2016. Inpatient MRI Performance Root Cause Analysis and Application of Lean Methodology to Improve Workflow. Oral Presentation. Conference. Inpatient MRI Performance Root Cause Analysis and Application of Lean Methodology to Improve Workflow. Oral Presentation, US.
- 2016. Increasing Workflow Efficiency by Reducing Turnaround Time for Orthopedic Patients with Same Day Imaging and Clinic Appointments. Oral Presentation. Conference. Increasing Workflow Efficiency by Reducing Turnaround Time for Orthopedic Patients with Same Day Imaging and Clinic Appointments. Oral Presentation, US.
- 2011. Total Glycolytic Activity of FDG PET/CT as Prognostic Biomarker of Outcome in Patients with Breast Cancer. Oral Presentation. Conference. Total Glycolytic Activity of FDG PET/CT as Prognostic Biomarker of Outcome in Patients with Breast Cancer. Oral Presentation, US.
- 2010. 18F-FLT PET/CT: Early Predictive Imaging Biomarker for Therapy Response. Oral Presentation. Conference. 18F-FLT PET/CT: Early Predictive Imaging Biomarker for Therapy Response. Oral Presentation, US.
International Presentations
- 2025. PSMA Imaging in Prostate Cancer. Invited. Chennai, IN.
- 2025. Theranostics in Prostate Cancer. Invited. Chennai, IN.
- 2024. Role of PSMA PET/CT and PET/MRI in Prostate Cancer. Invited. International Conference on Hybrid Imaging (IPET 2024). Vienna, AT.
- 2024. Interactive Case Discussion/ Tumor Board. Invited. International Conference on Hybrid Imaging (IPET 2024). Vienna, AT.
- 2024. PSMA PET Imaging and Theranostics in Prostate Cancer. Invited. 6th Annual Conference of Society of Oncological Imaging India SOIICON/European Society of Oncologic Imaging 2024. Secunderabad, IN.
Grant & Contract Support
| Date: | 2025 - 2032 |
| Title: | An expanded access program for the non-invasive detection of clear cell renal cell carcinoma (ccRCC) in patients with renal masses utilizing 89Zirconium-labelled girentuximab (89Zr-DFO-girentuximab) |
| Funding Source: | Telix Pharmaceuticals |
| Role: | PI |
| ID: | 2024-0270 |
| Date: | 2024 - Present |
| Title: | Phase II study of Lutetium Lu 177 dotatate in metastatic prostate cancer with neuroendocrine differentiation |
| Funding Source: | NCI protocol #10487 |
| Role: | Co-I |
| ID: | 2023-0827 |
| Date: | 2024 - 2031 |
| Title: | Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [ 177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers |
| Funding Source: | Novartis |
| Role: | Co-I |
| ID: | 2024-0549 |
| Date: | 2024 - 2027 |
| Title: | NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial |
| Funding Source: | Blue Earth Therapeutics |
| Role: | Co-I |
| ID: | 2022-0500 |
| Date: | 2023 - 2025 |
| Title: | Comprehensive Assessment of Cancer Theranostics Response; Investigating the Intent to Change Treatment Decisions Based on TRAQinform Theranostics |
| Funding Source: | AIQ Global Inc. (dba AIQ Solutions) |
| Role: | Co-I |
| ID: | 2024-1087 |
| Date: | 2022 - 2026 |
| Title: | Phase 1b/2 study of combination Lu177 girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC |
| Funding Source: | USA Medical Research Acq Activity |
| Role: | Co-I |
| ID: | 2021-0911 |
| Date: | 2022 - 2027 |
| Title: | A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177LuFAP-2286 in Patients with an Advanced Solid Tumor |
| Funding Source: | Novartis |
| Role: | Collaborator |
| ID: | 2020-1259 |
| Date: | 2022 - Present |
| Title: | An evidence-based focal cryotherapy protocol for focal ablation of intermediate risk prostate cancer (IIT) |
| Funding Source: | The University of Texas MD Anderson Cancer Center PRIME Funding |
| Role: | Co-I |
| ID: | 2022-0165 |
| Date: | 2021 - 2024 |
| Title: | A prospective pilot study investigating rhPSMA 7.3 PET/MRI in detecting recurrent disease and aid in radiotherapy planning in patients with biochemically recurrent prostate cancer |
| Funding Source: | Blue Earth Therapeutics Ltd |
| Role: | Principal Investigator (IIT) |
| ID: | 2020-1347 |
| Date: | 2020 - 2021 |
| Title: | A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy |
| Funding Source: | Blue Earth Diagnostics (BED 302) |
| Role: | Site Co-Investigator |
| ID: | 2020-0091 |
| Date: | 2020 - 2021 |
| Title: | A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer |
| Funding Source: | Blue Earth Diagnostics (BED 301) |
| Role: | Site Co-Investigator |
| ID: | 2019-1036 |
| Date: | 2015 - 2017 |
| Title: | Development of dissemination tools including decision tree algorithms to aid clinicians in making appropriate imaging decisions in lung, breast and colon cancer |
| Funding Source: | SNMMI AHRQ (Agency for Healthcare Research and Quality) Grant for Young Professionals |
| Role: | Chair, Lung Cancer Subcommittee |
Selected Publications
Peer-Reviewed Articles
- Moradpour M, Moradi Tuchayi A, Yadav S, Jiang F, Burger IA, Pop SG, Surasi DS, Hussein A, Arora I, Aparicio A, de Kouchkovsky I, Flavell RR, Hope TA. Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer. J Nucl Med, 2026. e-Pub 2026. PMID: 41786481.
- Horvat, N, Liu, PS, Fowler, KJ, Birkholz, JH, Cash, BD, Dane, B, Eng, C, Kambadakone, A, Korngold, E, Pietryga, JA, Refaat, T, Santillan, C, Surasi, DS, Woolsey, S, Kim, DH. ACR Appropriateness Criteria® Staging and Follow-up of Anal Cancer. Journal of the American College of Radiology 22(5):S396-S404, 2025. e-Pub 2025. PMID: 40409890.
- Moussa, MJ, Khandelwal, J, Wilson, NR, Malikayil, KL, Surasi, DS, Bathala, TK, Lin, Y, Rao, P, Tamboli, P, Sircar, K, Ajufo, HO, Elsayes, KM, Shah, AY, Johns, AC, Goswami, S, Hasanov, E, Jonasch, E, Msaouel, P, Campbell, M, Alhalabi, O, Tannir, NM. Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma. J Immunother Cancer 13(2), 2025. e-Pub 2025. PMID: 39939142.
- Moussa Mohammad J, Khandelwal J, Wilson NR, Malikayil KL, Surasi DS, Bathala TK, Lin Y, Ajufo H, Elsayes KM, Shah AY, Johns AC, Goswami S, Hasanov E, Jonasch E, Msaouel P, Campbell MT, Alhalabi O, Tannir NM. Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. J Immunother Cancer. e-Pub 2025.
- Fang AM, Gregg JR, Pettaway C, Ma J, Szklaruk J, Bathala TK, Surasi DSS, Chapin BF. Whole-body MRI for staging prostate cancer: a narrative review. BJU Int 135(1):13-21, 2025. e-Pub 2025. PMID: 39308142.
- Barker SJ, Soylu E, Allen BC, Auron M, Costa DN, Gerena M, Lotan Y, Rose TL, Solanki A, Surasi DS, Turkbey B, Whitworth P 3rd, Oto A. ACR Appropriateness Criteria(R) Pretreatment Staging of Urothelial Cancer: 2024 Update. J Am Coll Radiol 21(11S):S464-S489, 2024. e-Pub 2024. PMID: 39488355.
- Fang AM, Chapin BF, Shi CW, Sun J, Qayyum A, Kundra V, Corn PG, Kuban DA, Ravizzini GC, Surasi DSS, Ma J, Bathala TK. Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer. Prostate Cancer Prostatic Dis, 2024. e-Pub 2024. PMID: 39289537.
- Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis, 2024. e-Pub 2024. PMID: 39019979.
- Bommekal S, Flynt L, Tewari SO, Surasi DSS. PSMA-Avid Desmoid Tumor of the Abdominal Wall on 18 F-Piflufolastat PET/CT. Clin Nucl Med 49(7):672-673, 2024. e-Pub 2024. PMID: 38739529.
- Morris, MF, Henry, TS, Raptis, CA, Amin, AN, Auffermann, WF, Hatten, BW, Kelly, AM, Lai, AR, Martin, MD, Sandler, KL, Sirajuddin, A, Surasi, DS, Chung, J. ACR Appropriateness Criteria® Workup of Pleural Effusion or Pleural Disease. Journal of the American College of Radiology 21(6):S343-S352, 2024. e-Pub 2024. PMID: 38823955.
- Desai C, Clark A, Surasi DS, Flynt L. Detection of Adenocarcinoma of the Colon on 18 F-Fluciclovine PET/CT. Clin Nucl Med 49(6):543-545, 2024. e-Pub 2024. PMID: 38598733.
- Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment outcomes in patients with metastatic renal cell carcinoma with sarcomatoid and/or rhabdoid dedifferentiation after progression on immune checkpoint therapy. Oncologist 29(5):392-399, 2024. e-Pub 2024. PMID: 38035767.
- Fang AM, Jackson J, Gregg JR, Chery L, Tang C, Surasi DS, Siddiqui BA, Rais-Bahrami S, Bathala T, Chapin BF. Correction to: Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol 25(5):617-618, 2024. e-Pub 2024. PMID: 38642282.
- Fang AM, Jackson J, Gregg JR, Chery L, Tang C, Surasi DS, Siddiqui BA, Rais-Bahrami S, Bathala T, Chapin BF. Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol 25(1):66-83, 2024. e-Pub 2024. PMID: 38212510.
- Surasi DS, Kalva P, Hwang KP, Bathala TK. Pitfalls in prostate MR imaging interpretation. Radiol Clin N Am 62(1):53-67, 2024. e-Pub 2024. PMID: 37973245.
- Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Drazer M, Dwyre DM, Flagg A, Fournier D, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Karmali R, Karras N, Manchanda N, Morgan D, Ney DE, Raldow AC, Stefanovic A, Surasi DS, Tantravahi SK, Walkovich K, Yu JM, Zambidis E, Zhang L, Zurbriggen L, Awotiwon A, Freedman-Cass D. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Histiocytic Neoplasms V.2.2024, 2024. e-Pub 2024.
- Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF, Group LS. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). Eur Urol. e-Pub 2023. PMID: 37414702.
- Surasi DS. Localized prostate carcinoma with discordant findings on mpMRI and PSMA PET imaging. SNMMI/Urotoday Case of the Month, 2023. e-Pub 2023.
- Cardiac Imaging EPOVIA, Parenti VG, Vijay K, Maroules CD, Majdalany BS, Koweek LM, Khaja MS, Ghoshhajra BB, Agarwal PP, Contrella BN, Keefe NA, Lo BM, Malik SB, Surasi DS, Waite K, Williamson EE, Abbara S, Dill KE. ACR Appropriateness Criteria® Workup of Noncerebral Systemic Arterial Embolic Source. J Am Coll Radiol 20(5S):S285-S300, 2023. e-Pub 2023. PMID: 37236749.
- Musculoskeletal Imaging EPO, Garner HW, Wessell DE, Lenchik L, Ahlawat S, Baker JC, Banks J, Demertzis JL, Moon BS, Pierce JL, Scott JA, Sharda NK, Surasi DS, Temporal M, Chang EY. ACR Appropriateness Criteria® Soft Tissue Masses: 2022 Update. J Am Coll Radiol 20(5S):S234-S245, 2023. e-Pub 2023. PMID: 37236746.
- Musculoskeletal Imaging EPO, Nicholas N, Fox MG, Blankenbaker DG, Chen D, Frick MA, Jawetz ST, Mathiasen RE, Raizman NM, Rajkotia KH, Said N, Stensby JD, Subhas N, Surasi DS, Walker EA, Chang EY. ACR Appropriateness Criteria® Chronic Shoulder Pain: 2022 Update. J Am Coll Radiol 20(5S):S49-S69, 2023. e-Pub 2023. PMID: 37236752.
- Thomas JM, Chang EY, Ha AS, Bartolotta RJ, Bucknor MD, Caracciolo JT, Chen KC, Flug J, Kumaravel M, Raizman NM, Ross AB, Silvis ML, Surasi DS, Beaman FD. ACR Appropriateness Criteria® Chronic Elbow Pain. J Am Coll Radiol 19(11S):S256-S265, 2022. e-Pub 2022. PMID: 36436956.
- Raptis CA, Goldstein A, Henry TS, Porter KK, Catenacci D, Kelly AM, Kuzniewski CT, Lai AR, Lee E, Long JM, Martin MD, Morris MF, Sandler KL, Sirajuddin A, Surasi DS, Wallace GW, Kamel IR, Donnelly EF. ACR Appropriateness Criteria® Staging and Follow-Up of Esophageal Cancer. J Am Coll Radiol 19(11S):S462-S472, 2022. e-Pub 2022. PMID: 36436970.
- Parsons MS, Policeni B, Juliano AF, Agarwal M, Benjamin ER, Burns J, Doerr T, Dubey P, Friedman ER, Gule-Monroe MK, Gutowski KA, Hagiwara M, Jain V, Rath TJ, Shian B, Surasi DS, Taheri MR, Zander D, Corey AS. ACR Appropriateness Criteria Imaging of Facial Trauma Following Primary Survey. J Am Coll Radiol 19(5S):S67-S86, 2022. e-Pub 2022. PMID: 35550806.
- Ranasinghe WKB, Troncoso P, Surasi DS, Ibarra Rovira JJ, Bhosale P, Szklaruk J, Kokorovic A, Wang X, Elsheshtawi M, Zhang M, Aparicio A, Chapin BF, Bathala TK. Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. Radiology 303(1):110-118, 2022. e-Pub 2022. PMID: 35076303.
- Surasi DS, Lin L, Ravizzini G, Wong F. Supraclavicular and Axillary Lymphadenopathy Induced by COVID-19 Vaccination on 18F-Fluorthanatrace, 68Ga-DOTATATE, and 18F-Fluciclovine PET/CT. Clin Nucl Med 47(2):195-196, 2022. e-Pub 2022. PMID: 34507331.
- Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol 27(47):8166-8181, 2021. e-Pub 2021. PMID: 35068861.
- Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer 19(6):e401-e408, 2021. e-Pub 2021. PMID: 34625389.
- Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34885132.
- Yadav D, Shah K, Naidoo K, Surasi DS. PET/Computed Tomography in Thyroid Cancer. Neuroimaging Clin N Am 31(3):345-357, 2021. e-Pub 2021.
- Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34326169.
- Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33946504.
- Surasi DS, Wang X, Bathala TK, Hwang H, Arora S, Westphalen AC, Chang SD, Turkbey B. The impact and collateral damage of COVID-19 on prostate MRI and guided biopsy operations: Society of Abdominal Radiology Prostate Cancer Disease-Focused Panel survey analysis. Abdom Radiol (NY). e-Pub 2021. PMID: 33904992.
- Guirguis MS, Adrada BE, Surasi DS, Dryden MJ. 68Ga-DOTATATE Uptake in Primary Breast Cancer. Clin Nucl Med 46(3):248-249, 2021. e-Pub 2021. PMID: 33234932.
- Surasi DSS, Lu Y, Corn P, Pettaway C, Bathala T. Incidental Detection of Urothelial Carcinoma on 18F-Fluciclovine PET/CT. Clin Nucl Med 46(2):e114-e115, 2021. e-Pub 2021. PMID: 33156041.
- Gregg JR, Surasi DS, Childs A, Moll N, Ward JF, Kim J, Daniel CR, Logothetis C, Bathala T, Davis JW. The Association of Periprostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance. J Urol 205(1):122-128, 2021. e-Pub 2021. PMID: 32718204.
- Surasi DSS. Editorial Comment on "Diagnostic accuracy of 68Ga-PSMA PET/CT for initial detection in patients with suspected prostate cancer: A systematic review and meta-analysis". AJR Am J Roentgenol. e-Pub 2020. PMID: 32812791.
- Surasi DSS, Chapin B, Tang C, Ravizzini G, Bathala TK. Imaging and Management of Prostate Cancer. Semin Ultrasound CT MR 41(2):207-221, 2020. e-Pub 2020. PMID: 32446432.
- Surasi DSS, Jazbeh S, Nicek ZS, Zanabria RG, Wells RT, Patel A, Alhyari L, Wagner JM. Utility of Longitudinal Measurement of the Liver With Ultrasound in Comparison to Computed Tomography Liver Volume in Assessing Hepatomegaly. Ultrasound Q. e-Pub 2019. PMID: 31517741.
- Surasi DS, Manapragada PP, Lloyd SG, Bhambhvani P. Role of multimodality imaging including Thallium-201 myocardial perfusion imaging in the diagnosis and monitoring of treatment response in cardiac sarcoidosis. J Nucl Cardiol 21(4):849-52, 2014. e-Pub 2014. PMID: 24493414.
- Surasi DS, Peller PJ, Szabo Z, Mercier G, Subramaniam RM. Dopamine Transporter SPECT Imaging in Parkinson Disease and Dementia. PET Clin 8(4):459-67, 2013. e-Pub 2013. PMID: 27156473.
- Surasi DS, Lam S, Subramaniam RM. F-18 FDG PET/CT imaging of a hidradenocarcinoma of head and neck. Clin Nucl Med 36(10):945-7, 2011. e-Pub 2011. PMID: 21892057.
- Surasi DS, Meibom S, Grillone G, Subramaniam RM. F-18 FDG PET/CT imaging of a parapharyngeal hemangioma. Clin Nucl Med 35(8):612-3, 2010. e-Pub 2010. PMID: 20631514.
- Lin SH, Corn P, Yu G, Zhang M, Troncoso P, Surasi DS, Liu S, Logothetis C, Wang G, Panaretakis T, Fan Y, Ajani JA. Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment. Prostate Cancer Prostatic Dis.
Invited Articles
- Abreu-Gomez J, Eberhardt SC, Chapin BF, Fennesy FM, Surasi DS, Weg ES, Wang H, Westphalen AC. MRI for Prostate Cancer Local Staging: AJR Expert Panel Narrative Review. Am J Roentgenol. e-Pub 2025.
Review Articles
- Yadav D, Hwang H, Qiao W, Upadhyay R, Chapin BF, Tang C, Aparicio A, Lopez-Olivo MA, Kang SK, Macapinlac HA, Bathala TK, Surasi DS. 18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer 4(2):e210091, 2022. e-Pub 2022. PMID: 35212559.
- Taher A, Jensen CT, Yedururi S, Surasi DS, Faria SC, Bathala TK, Mujtaba B, Bhosale P, Wagner-Bartak N, Morani AC. Imaging of Neuroendocrine Prostatic Carcinoma. Cancers (Basel) 13(22), 2021. e-Pub 2021. PMID: 34830919.
- Surasi DS, O'Malley JP, Bhambhvani P. 18F-FDG PET/CT Findings in Portal Vein Thrombosis and Liver Metastases. J Nucl Med Technol 43(3):229-30, 2015. e-Pub 2015. PMID: 25655342.
- Surasi DS, O'Malley J, Bhambhvani P. 99mTc-Tilmanocept: A Novel Molecular Agent for Lymphatic Mapping and Sentinel Lymph Node Localization. J Nucl Med Technol 43(2):87-91, 2015. e-Pub 2015. PMID: 25956693.
- Surasi DS, Manapragada P, Bhambhvani P. Lung perfusion imaging in hepatopulmonary syndrome using (99m)Tc macroaggregated albumin. J Nucl Cardiol 22(3):586-8, 2015. e-Pub 2015. PMID: 25164140.
- Marcus C, Whitworth PW, Surasi DS, Pai SI, Subramaniam RM. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol 202(6):1316-29, 2014. e-Pub 2014. PMID: 24848831.
- Surasi DS, Bhambhvani P, Baldwin JA, Almodovar SE, O'Malley JP. ¹8F-FDG PET and PET/CT patient preparation: a review of the literature. J Nucl Med Technol 42(1):5-13, 2014. e-Pub 2014. PMID: 24503347.
- Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors, Part 2. AJR Am J Roentgenol 197(2):W260-5, 2011. e-Pub 2011. PMID: 21785051.
- Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of liver metastases, Part 1. AJR Am J Roentgenol 197(2):W256-9, 2011. e-Pub 2011. PMID: 21785050.
- Davison JM, Subramaniam RM, Surasi DS, Cooley T, Mercier G, Peller PJ. FDG PET/CT in patients with HIV. AJR Am J Roentgenol 197(2):284-94, 2011. e-Pub 2011. PMID: 21785073.
Other Articles
- Park P, Gao M, Wang X, Hwang H, Surasi DS, Anderson M, Ibarra J, Javadi S, Morani S, Szklaruk J, Marcal J, Surabhi V, Bhosale P, Adidi M, Chapin B, Chery L, Papadopoulos J, Pettaway C, Ward J, Ma J, Tang C, Choi S, Zhang M, Pisters L, Troncoso P, Bathala TK Diagnostic performance of multiparametric MRI in radio-recurrent prostate cancer using the Prostate Imaging for Recurrence Reporting (PI-RR) and histopathologic correlation. 2022 Society of Abdominal Radiology (SAR) Annual Meeting, 2022.
- Wilson N, Wiele A, Surasi DS, Rao P, Sircar K, Shah A, Genovese G, Karam J, Wood C, Tannir N, Msaouel P Efficacy of Gemcitabine plus Doxorubicin (Gem + Dox) in Patients with Renal Medullary Carcinoma (RMC). Genitourinary Cancer Symposium ASCO 2021, 2021.
- Hahn AW, Tidwell RS, Surasi DS, Pilie P, Frigo DE, Subudhi SK, Efstathiou E, Zurita-Saavedra AJ, Tu S, Chapin BF, Fogelman D, Starbuck MW, Corn PG, Aparicio A, McQuade J, Logothetis C Adiposity and response to androgen signaling inhibition (ASI) in men with metastatic castration-resistant prostate cancer (mCRPC). ASCO Genitourinary Cancer Symposium 2021, 2021.
- Hahn A, Tidwell R, Surasi DS, Msaouel P, Efstathiou E, Zurita-Saavedra A, Shi-Ming T, McQuade J, Fogelman D, Starbuck M, Subudhi S, Corn P, Pilie P, Aparicio A, Logothetis C Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). ESMO Virtual Congress 2020 Science Weekend, 2020.
- Yedururi S, Morani A, Hyun J, Leonrado M, Surasi DS, Katabathina V, Prasad S The molecular subtypes of Pheochromocytoma and Paraganglioma (PPGL): The Cancer Genome Atlas (TCGA) transcriptome data derived taxonomic scheme and 2017 WHO classification system. Radiological Society of North America (RSNA) 2019 Annual Meeting, 2019.
- Surasi DS, Cornwell B, Hughes J Cavernous Sinus thrombosis. AJNR Classic case, 2018.
- Surasi DS, McNamara M, Langston M, Bhambhvani P, O'Malley J 18F-FDG PET/CT Imaging of Pancreatic Carcinoma: A Pictorial Review. The Association of University Radiologists (AUR) Annual Meeting, 2014.
- Palot Manzil FF, Azure MT, Almodovar-Retegius, SE, Manapragada P, Bhambhvani PG, Surasi DS, OMalley JP Safety First! Radiation safety concerns and regulations for alpha emitter therapy. Radiological Society of North America (RSNA) Annual Meeting, 2013.
- Surasi DS, Peller PJ, Mercier GA, Subramaniam RM Dopamine Transporter SPECT Imaging in Parkinsons Disease. Radiological Society of North America (RSNA) Annual Meeting.
- Davison JM, Peller PJ, Dibble E, Jackson T, Surasi DS, Mercier GA, Subramaniam RM FDG PET/CT in the Evaluation and Management of HIV Positive Patients. Radiological Society of North America (RSNA) Annual Meeting.
- Surasi DS, Combs JT, Baldwin JA, Almodovar SE, Bhambhvani P, O'Malley JP Nuclear Medicine Imaging of the Lymphatic System: Update 2012. Southeastern Chapter Society of Nuclear Medicine Annual Meeting.
- Manapragada P, Surasi DS, Palot Manzil FF, O'Malley JP, Almodovar-Retegius SE Alpha Particles 2013: Current perspectives on alpha particle mediated therapies. Radiological Society of North America (RSNA) Annual Meeting.
- Manapragada PM, Surasi DS, Bhambhvani P, Baldwin J, O'Malley JP, Almodovar S Review of radioisotope imaging of primary and secondary malignant osseous lesions with F18-FDG PET/CT, F18-sodium fluoride bone PET/CT and Tc-99m bone scan. Radiological Society of North America (RSNA) Annual Meeting.
- Surasi DS, O'Malley JP, Langston M, Baldwin J, Bhambhvani P, Almodovar S Value of FDG PET/CT in the evaluation of Langerhans cell histiocytosis. Southeastern Chapter Society of Nuclear Medicine Annual Meeting.
- McArthur TA, Surasi DS, Huang C, Langston M Intra-Articular and Peri-articular Masses: A Spectrum of Multi-Modality Imaging Findings. American Roentgen Ray Society 2015 Annual Meeting.
- Graham A, Surasi DS, Elkaissi M Chronic Cranial Neuropathy - Case Presentation. Oklahoma State Radiological Society Annual Meeting.
- Sims H, Surasi DS, Utturkar A, Graham A, Elkaissi Basilar Artery Occlusion: Case Discussion. Oklahoma State Radiological Society Annual Meeting.
- Sims H, Surasi DS, Utturkar A, Graham A, Elkaissi Vertebral Artery Hypoplasia and Occlusion. Case Discussion. Oklahoma State Radiological Society Annual Meeting.
- Graham A, Surasi DS, Elkaissi M Acute Cranial Neuropathy - Case Presentation. Oklahoma State Radiological Society Annual Meeting.
- Surasi DS, Lindsey A, Mason N Multimodality Imaging of Pheochromocytoma. Oklahoma State Radiological Society Annual Meeting.
- Surasi DS, Peller PJ, Lee S, Mercier GM, Subramaniam RM Value of PET/CT molecular imaging in the management of thyroid carcinoma. The American Society of Neuroradiology (ASNR) Annual Meeting.
- Davison JM, Surasi DS, Grillone G, Subramaniam RM 18FDG standardized uptake value ratio as a biomarker for differentiating squamous cell carcinoma of the base of tongue from physiological uptake. The Association of University Radiologists (AUR) Annual Meeting.
- Surasi DS, Subramaniam RM, Truong MT, Peller PJ, Mercier G 18F-FLT PET/CT: Early predictive imaging biomarker for therapy response. The American Roentgen Ray Society (ARRS) Annual Meeting.
- Davison JM, Surasi DS, Cooley T, Subramaniam RM The value of FDG-PET/CT in the management of HIV-related malignancies. The American Roentgen Ray Society (ARRS) Annual Meeting.
- Surasi DS, Subramaniam RM, Truong MT, Russo G, Peller PJ, Mercier G FDG PET/CT and FLT PET/CT in the early prediction of tumor response. Radiological Society of North America (RSNA) Annual Meeting.
- Bathala TK, Kabutey NK, Surasi DS, Kim D Chronic lower extremity venous disease: Classification, Diagnosis and endovascular treatment. Radiological Society of North America (RSNA) Annual Meeting.
Abstracts
- Surasi DS, McArthur T, Langston M. 18F-FDG PET/CT and Musculoskeletal findings: Pearls and Pitfalls. J Nucl Med. Meeting Abstracts 56(supplement 3):1899, 2015. e-Pub 2015.
- Manapragada P, Surasi DS, Druhan J, O J, Bhambhvani P, Baldwin J, Almodovar S. Salivary gland scintigraphy: Rediscovering an underutilized diagnostic aid. J Nucl Med. Meeting Abstracts 55(supplement 1):1273, 2014. e-Pub 2014.
- Manapragada P, Bhambhvani P, Surasi DS, Druhan J, Almodovar S, Baldwin J, O J. Gallium 67 SPECT as a treatment monitoring tool in temporal bone and skull base osteomyelitis. J Nucl Med. Meeting Abstracts 55(supplement 1):1973, 2014. e-Pub 2014.
- Druhan J, Manapragada P, Surasi DS, O J, Bhambhvani P, Baldwin J, Almodovar S. Special considerations when performing and interpreting FDG PET/CT studies in patients with Li-Fraumeni syndrome. J Nucl Med. Meeting Abstracts 55(supplement 1):1349, 2014. e-Pub 2014.
- Surasi DS, Manapragada P, Druhan J, 0 J, Sullivan J, Bhambhvani P, Baldwin J, Almodovar S. Rad-path correlation of DaT SPECT imaging with MRI and post-mortem tissue findings in the evaluation of tremor disorders. J Nucl Med. Meeting Abstracts 55(supplement 1):1267, 2014. e-Pub 2014.
- Palot Manzil FF, Hinshelwood J, Manapragada P, Surasi DS, O'Malley J, Bhambhvani P, Baldwin J, Almodovar S. The role of Y90 sphere therapies in the treatment of hepatic malignancies. J Nucl Med. Meeting Abstracts 54(supplement 2):1286, 2013. e-Pub 2013.
- Palot Manzil FF, Manapragada P, Surasi DS, Hinshelwood J, O'Malley J, Bhambhvani P, Baldwin J, Almodovar S. Correlation of biology, receptor status and FDG uptake in PET/CT for breast malignancies. J Nucl Med. Meeting Abstracts 54(supplement 2):1303, 2013. e-Pub 2013.
- Subramaniam R, Surasi DS, Mercier G. Tumor metabolic volume and total glycolytic activity and outcome in patients with breast cancer. J Nucl Med. Meeting Abstracts 52(supplement 1):1809, 2011. e-Pub 2011.
- Mercier G, Surasi DS. Kinetic analysis of gastric pouch emptying after bariatric surgery. J Nucl Med. Meeting Abstracts 52(supplement 1):1360, 2011. e-Pub 2011.
- Andrews JR, Surasi DS, Mawlawi O, Pilie P, Subudhi S, Siddiqui B, Chapin BF. The Nautilus Trial: A Forthcoming MD Anderson Phase 1/2 Neoadjuvant Theranostic Lutetium-177 PSMA Trial. UT Christopher G. Wood Advances in Urologic Oncology.
- DeSai C, Flynt L, Jessop A, Wong F, Xu G, Tewari S, Chen B, Wan D, Surasi DS. Optimization of Lu-177 PSMA Post-Therapy Imaging Time. 2024 ACR Meeting.
- Surasi DS, Shi C, Gao M, Sun J, Anderson M, Ibarra-Rovira J, Javadi S, Morani A, Szklaruk J, Marcal L, Surabhi V, Bhosale P, Chapin B, Papadopoulos J, Davis J, Ward J, Tang C, Mok H, Frank S, Ma J, Zhang M, Pisters L, Troncoso P, Bathala T. Diagnostic performance of multiparametric MRI in the evaluation of recurrent prostate cancer following LDR brachytherapy using the Prostate Imaging for Recurrence Reporting guidelines (PI-RR) and histopathologic correlation. 2024 SAR Annual Meeting.
- Ansari M, Hoffman K, Mok H, Frank S, Nguyen Q, Tang C, McGuire S, Mayo L, Shah S, Prajapati S, Surasi DS, Pilie P, Lozano C, Mohamad O, Choi S, Hassanzadeh C. Clinical Outcomes of Salvage Nodal Radiotherapy for Prostate Cancer with Prior Radiotherapy. 2025 ASTRO Annual Meeting.
- Fang A, Chapin B, Shi C, Sun J, Qayyum A, Kundra V, Corn P, Kuban D, Ravizzini G, Surasi DS, Ma J, Bathala T. Whole-Body Magnetic Resonance Imaging for Staging Patients with High-Risk Prostate Cancer. The Society of Urologic Oncology (SUO) 2024 Annual Meeting.
- Moussa MJ, Khandelwal J, Wilson N, Malikayil K, Surasi D, Bathala T, Lin Y, Ajufo H, Elsayes K, Shah A, Johns A, Goswami S, Hasanov E, Jonasch E, Msaouel P, Campbell M, Alhalabi O, Tannir N. Efficacy and safety of nivolumab plus ipilimumab (Nivo/Ipi) in patients with metastatic variant histology renal cell carcinoma. 2025 ASCO Genitourinary Cancers Symposium.
- Janda G, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Diamond EL, Drazer M, Dwyre DM, Flagg A, Fournier D, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Karmali R, Karras N, Lee J, Manchanda N, Morgan D, Ney D, Raldow AC, Raulji C, Stefanovic A, Surasi DS, Tantravahi SK, Walkovich K, Yu J, Zambidis E, Zhang L, Zurbriggen L, Go R. Global Utilization of the National Comprehensive Cancer Network Clinical Practice Guidelines for Histiocytic Neoplasms. 10th Annual Erdheim Chester Disease (ECD) Medical Symposium.
- Shin K, Choi S, Hassanzadeh C, Hoffman K, McGuire S, Mohamad O, Mok H, Nguyen QN, Park R, Tang C, Zurita-Saavedra A, Chapin B, Surasi DS. Treatment Outcomes of Radiation Therapy with Androgen Deprivation Therapy in Patients with N1 Prostate Cancer. 2025 ASTRO Annual Meeting.
Book Chapters
- Subramaniam RM, Davison JM, Surasi DS, Russo G, Peller PJ. Chest. In: PET/CT and PET/MRI in Oncology. 1st Edition. Springer, 77-100, 2012.
- Subramaniam RM, Davison JM, Surasi DS, Jackson T, Cooley T. Patients with HIV. In: PET/CT and PET/MRI in Oncology. 1st Edition. Springer, 379-398, 2012.
- Surasi DS, Sacks A, Davison J, Agarwal A, Mehta A, Ryan T, Filitis D, Subramaniam R. Chapter 13: PET/CT (9 cases). In: Head and Neck Imaging Cases. McGraw-Hill, 2011.
- Aparicio A, Pilie P, Surasi DS, Choi S, Chapin B, Logothetis C, Corn P. Neoplasms of the prostate. In: Holland-Frei Cancer Medicine. 10th Edition. Wiley-Blackwell.
Patient Reviews
CV information above last modified March 09, 2026